Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 1Breast 1

Conditions

Sarcoma 2

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 11Cyclophosphamide 11Biopsy 9Radiation 8atezolizumab 7Temozolomide 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5pembrolizumab 4Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
anlotinib × Sarcoma × 30 days × Clear all
NCT07612098 2026-05-28

SPARE-04

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
274 enrolled
Sarcoma

Sarcoma

NCT05301764 2026-05-20

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Lyvgen Biopharma Holdings Limited

Phase 1/2 Completed
39 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡